| DRG | Dorsal Root Ganglia |
|---|---|
| DRG | diagnosis-related group; Division of Research Grants [NIH}; dorsal respiratory group; dorsal root ga... |
| drg | drainage |
| PM-DRG | pediatric modified diagnosis-related group |
| KUN | Kunjin |
|---|---|
| KUN | Kunjin virus |
| AN-DRG | Australian National Diagnosis Related Group |
| DRG | Diagnosis Related Group |
| DRG | Diagnostic Related Group |
| famotidine | <chemical> 3-(((2-((aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-n-(aminosulfonyl)propanimidamide. A competitive histamine h2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion. The drug does not affect cardiovascular, renal, endocrine, pancreatic exocrine, or gastrointestinal motility functions. No clinically important interactions with other drugs have been described. It is an effective agent in the therapy of duodenal, gastric, and peptic ulcer, as well as of zollinger-ellison syndrome. Pharmacological action: anti-ulcer agents, histamine h2 antagonists. Chemical name: Propanimidamide, 3-(((2-((aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)- (12 Dec 1998) |
|---|---|
| DRG | <abbreviation> Diagnosis-related group. (05 Mar 2000) |
| outliers, drg | In health care reimbursement, especially in the prospective payment system, those patients who require an unusually long hospital stay or whose stay generates unusually high costs. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|---|---|---|---|
|
한국유나이티드파모티딘정20mg - 새창
|
한국유나이티드제약 |
A12902031 | Famotidine | 전문의약품 | 급여 |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|